Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shanghai Raising Pharmaceutical Co. Ltd. currently faces 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution is handled by 1 distinct examiner and 1 distinct art unit. O DELL, DAVID K is the busiest examiner for the company, currently reviewing the pending matter.
Because the portfolio is limited to a single distinct examiner, the company's current USPTO interaction is highly centralized. This focus is beneficial for ensuring that technical arguments remain consistent across the prosecution record. For a practitioner, this means that the response strategy can be tailored to the specific preferences and examination style of the assigned official. The 1 pending action represents a focused attempt to secure intellectual property in the biotechnology sector.
The involvement of only a single art unit simplifies the management of the application, as the applicant only needs to navigate the precedents of one administrative group. This streamlined approach can lead to a more predictable examination process. By concentrating resources on this 1 pending action, the company can ensure that its technical claims are thoroughly addressed within the specialized framework of the Biotechnology & Pharmaceuticals area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18561909 | Compound containing phosphate group, pharmaceutical composition containing same, preparation method therefor and use thereof | O DELL, DAVID K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18561909 | Compound containing phosphate group, pharmaceutical composition containing same, preparation method therefor and use thereof | O DELL, DAVID K | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18561909 | Compound containing phosphate group, pharmaceutical composition containing same, preparation method therefor and use thereof | O DELL, DAVID K | 1621 | §101§102§103§112DP | Non-Final OA | — | Pending | Nov 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial